Search research articles
Contact Us
Filters
Showing results (261-270 of 275) with videos related to
Page
of 28
Sort By:
Leukemia Research
|
September 4, 1999
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study
C Karanes, K J Kopecky, D R Head, et al.
Pharmaceutical Research
|
December 1, 1988
An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model
S A Gruber, R J Cipolle, D M Canafax, et al.
Transplantation
|
December 1, 1989
The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model
S A Gruber, D M Canafax, G R Erdmann, et al.
Cancer Chemotherapy and Pharmacology
|
November 7, 1999
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study
S M Grunberg, J Crowley, K R Hande, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
August 4, 2011
FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone
Simon Wöhrle, Olivier Bonny, Noemie Beluch, et al.
Cancer Research
|
March 5, 2008
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics
Patrizia Sini, Ivana Samarzija, Fabienne Baffert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program
Gary R Morrow, Jane T Hickok, Joseph A Roscoe, et al.
Blood
|
October 15, 1996
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
J K Weick, K J Kopecky, F R Appelbaum, et al.
Neuro-Oncology
|
February 6, 2018
SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment
Gerald Moncayo, Michal Grzmil, Tatiana Smirnova, et al.
Blood
|
November 24, 2001
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
A F List, K J Kopecky, C L Willman, et al.
Page
of 28
Search research articles
Search
Showing results (261-270 of 275) with videos related to
Sort By:
Page
of 28
Leukemia Research
|
September 4, 1999
A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study
C Karanes, K J Kopecky, D R Head, et al.
Pharmaceutical Research
|
December 1, 1988
An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model
S A Gruber, R J Cipolle, D M Canafax, et al.
Transplantation
|
December 1, 1989
The pharmacokinetic advantage of local 6-mercaptopurine infusion in a canine renal transplant model
S A Gruber, D M Canafax, G R Erdmann, et al.
Cancer Chemotherapy and Pharmacology
|
November 7, 1999
Treatment of poor-prognosis extensive disease small-cell lung cancer with an all-oral regimen of etoposide and cyclophosphamide - a Southwest Oncology Group clinical and pharmacokinetic study
S M Grunberg, J Crowley, K R Hande, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research
|
August 4, 2011
FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone
Simon Wöhrle, Olivier Bonny, Noemie Beluch, et al.
Cancer Research
|
March 5, 2008
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics
Patrizia Sini, Ivana Samarzija, Fabienne Baffert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program
Gary R Morrow, Jane T Hickok, Joseph A Roscoe, et al.
Blood
|
October 15, 1996
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study
J K Weick, K J Kopecky, F R Appelbaum, et al.
Neuro-Oncology
|
February 6, 2018
SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment
Gerald Moncayo, Michal Grzmil, Tatiana Smirnova, et al.
Blood
|
November 24, 2001
Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study
A F List, K J Kopecky, C L Willman, et al.
Page
of 28